This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Osama Chahrour, Ph.D.
Senior New Modalities Leader at AstraZeneca


Dr. Osama Chahrour is a senior leader of the analytical services for synthetic peptides at the chemical development department- AstraZeneca. He is an active member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) MQEG CMC Sub-team and of the international consortium for innovation and quality in pharmaceutical development (IQ) Peptide Working Group NDA/BLA sub team. His success has been reflected in published patents, peer reviewed papers and posters. His interests focus on analytical support for CMC programs in several therapeutic areas, leading associated analytical services that support this long process during clinical trial and commercial launch. He is particularly interested in forging multidisciplinary approaches for drug substance and drug product testing incorporating mass spectrometry (MS)-based identification and quantitation of molecules.

After receiving his Pharm.D in 2002, Osama spent four years in one of the world-leading multinational pharmaceutical company as analytical scientist. He helped in implementing techniques to serve multiple analytical purposes e.g. quantification of contaminants, peptide sequencing, metabolite identification/quantification, and trace impurities structural elucidation. In 2007, he joined the University of Nottingham as PhD researcher at the School of Pharmacy. Between 2011 and 2022, Osama led analytical teams in multiple CROs such as Almac, FERA and ACM global labs, where he implemented in-depth analysis expertise to meet customer requirements, including characterisation (amino-acid sequence, peptide mapping, disulfide bridges mapping and post-translation modification by broad range of digest strategies followed by LC-MS/MS), physicochemical properties determination (molecular weight, isoform pattern and spectroscopic profiles) and product related impurity analysis (truncates and host cell protein determination).

Agenda Sessions

  • Challenges and Solutions in Peptide Reference Standards Characterization, Establishment, Purity Assignment and Usage During Clinical Development Programmes